---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Mechanism of action"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Mechanism of action. Topics: Mechanism of action: prescribing information, Mechanism of action: manufacturer description at approval, Restoration of cholesterol trafficking in the central nervous system: company nonclinical studies, and Cyclodextrins as lipid-mobilizing agents. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Mechanism of action: prescribing information

> “The mechanism(s) by which LEMBAZ exerts its clinical effects to reduce the risk of mortality in adult and pediatric patients who weigh 7 kg or greater with NPC with neurological manifestations that started at less than 6 years old has not been fully characterized.”
> “Adrabetadex has binding affinity for cholesterol and reduces lipid and ganglioside accumulation in the context of NPC by trafficking cholesterol out of the lysosome.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.6.1-2"></a>

### Mechanism of action: manufacturer description at approval

> “LEMBAZ targets the cholesterol that builds up inside brain cells, which drives the neurological damage in NPC, by replacing the function of the NPC protein that is not working properly and helps move cholesterol to where the cell can use it.”
> “By re-establishing intracellular cholesterol trafficking, LEMBAZ addresses the underlying cause of NPC.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.1.2.6.1-3"></a>

### Restoration of cholesterol trafficking in the central nervous system: company nonclinical studies

> “Adrabetadex re-establishes intracellular cholesterol trafficking within the CNS, addressing the central pathogenic defect in I-NPC and supporting its potential as foundational therapy.”
> “Adrabetadex is an investigational intrathecal therapy for infantile-onset NPC (I-NPC; neurological onset <6 years of age) and the only therapy designed to directly target accumulated intracellular cholesterol in the CNS, the central pathogenic driver of NPC.”

Source: [Burchard et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P18.1-MOA.pdf)

<a id="topic-2.1.2.6.1-4"></a>

### Cyclodextrins as lipid-mobilizing agents

> “Recently, uncomplexed cyclodextrins have emerged as potent therapeutic compounds in their own right, based on their ability to sequester and mobilize cellular lipids.”
> “In particular, 2-hydroxypropyl-β-cyclodextrin (HPβCD) has garnered attention because of its cholesterol chelating properties, which appear to treat a rare neurodegenerative disorder and to promote atherosclerosis regression related to stroke and heart disease.”

Source: [Crumling et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5676048/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
